A Practical Diligence Framework for Early Medtech and Life-Science Deals
Six questions that separate real technical risk from a polished deck.
Read article →Insights
Notes on preclinical rigor, applied AI, and evaluating early-stage science.
What Biotech Teams Should Automate First with AI
A priority order for AI in biotech — highest-leverage, lowest-risk first.
Read article →Why Preclinical Studies Fail Investors Before They Fail Science
The most common reasons a preclinical package dies in diligence — and how to design around them.
Read article →